Clinical and molecular characteristics at diagnosis according to BAALC and ERG expression status in older CN-AML patients
| Characteristic . | Low BAALC (n = 79) . | High BAALC (n = 79) . | P . | Low ERG (n = 79) . | High ERG (n = 79) . | P . |
|---|---|---|---|---|---|---|
| Age, y | .17 | .95 | ||||
| Median | 67 | 69 | 68 | 69 | ||
| Range | 60-79 | 60-83 | 60-81 | 60-83 | ||
| Sex, no. (%) | .52 | .11 | ||||
| Male | 46 (58) | 41 (52) | 38 (48) | 49 (62) | ||
| Female | 33 (42) | 38 (48) | 41 (52) | 30 (38) | ||
| Race, no. (%) | .40 | 1.0 | ||||
| White | 73 (94) | 68 (89) | 70 (92) | 71 (91) | ||
| Nonwhite | 5 (6) | 8 (11) | 6 (8) | 7 (9) | ||
| Hemoglobin, g/dL | .43 | .76 | ||||
| Median | 9.6 | 9.5 | 9.5 | 9.5 | ||
| Range | 5.4-15.0 | 6.8-14.5 | 5.4-13.6 | 6.0-15.0 | ||
| Platelet count, ×109/L | .31 | .51 | ||||
| Median | 55 | 67 | 69 | 55 | ||
| Range | 5-481 | 4-850 | 4-271 | 11-850 | ||
| WBC count, ×109/L | .78 | .005 | ||||
| Median | 27.8 | 33.5 | 20.6 | 38.0 | ||
| Range | 1.4-450.0 | 1.0-173.1 | 1.1-234.5 | 1.0-450.0 | ||
| Blood blasts, % | .36 | < .001 | ||||
| Median | 52 | 59 | 34 | 68 | ||
| Range | 0–97 | 0–99 | 0–93 | 0–99 | ||
| BM blasts, % | .80 | .001 | ||||
| Median | 70 | 67 | 59 | 75 | ||
| Range | 11-97 | 7-97 | 7-97 | 23-97 | ||
| Extramedullary involvement, no. (%) | 16 (21) | 19 (25) | .70 | 16 (21) | 19 (25) | .56 |
| NPM1, no. (%) | < .001 | .33 | ||||
| Mutated | 64 (81) | 33 (42) | 45 (57) | 52 (66) | ||
| Wild-type | 15 (19) | 46 (58) | 34 (43) | 27 (34) | ||
| FLT3-ITD, no. (%) | .14 | < .001 | ||||
| Present | 24 (30) | 34 (43) | 12 (15) | 46 (58) | ||
| Absent | 55 (70) | 45 (57) | 67 (85) | 33 (42) | ||
| FLT3-TKD, no. (%) | .61 | .61 | ||||
| Present | 10 (13) | 7 (9) | 10 (13) | 7 (9) | ||
| Absent | 69 (87) | 72 (91) | 69 (87) | 72 (91) | ||
| WT1, no. (%) | .21 | .21 | ||||
| Mutated | 3 (4) | 8 (10) | 3 (4) | 8 (10) | ||
| Wild-type | 76 (96) | 71 (90) | 76 (96) | 71 (90) | ||
| CEBPA, no. (%) | .02 | .65 | ||||
| Mutated | 6 (8) | 17 (22) | 10 (13) | 13 (16) | ||
| Wild-type | 73 (92) | 62 (78) | 69 (87) | 66 (84) | ||
| IDH1, no. (%) | .09 | .40 | ||||
| Mutated | 4 (6) | 10 (17) | 5 (8) | 9 (15) | ||
| Wild-type | 59 (94) | 50 (83) | 59 (92) | 53 (85) | ||
| IDH2*, no. (%) | .30 | .10 | ||||
| R140 IDH2 | 18 (29) | 7 (12) | 17 (28) | 8 (13) | ||
| R172 IDH2 | 0 (0) | 5 (8) | 2 (3) | 3 (5) | ||
| Wild-type | 45 (71) | 48 (80) | 42 (69) | 51 (82) | ||
| MLL-PTD, no. (%) | .68 | .42 | ||||
| Present | 2 (4) | 4 (7) | 4 (7) | 2 (3) | ||
| Absent | 55 (96) | 55 (93) | 51 (93) | 59 (97) | ||
| ERG expression†, no. (%) | < .001 | |||||
| Low | 51 (65) | 28 (35) | ||||
| High | 28 (35) | 51 (65) | ||||
| BAALC expression†, no. (%) | < .001 | |||||
| Low | 51 (65) | 28 (35) | ||||
| High | 28 (35) | 51 (65) |
| Characteristic . | Low BAALC (n = 79) . | High BAALC (n = 79) . | P . | Low ERG (n = 79) . | High ERG (n = 79) . | P . |
|---|---|---|---|---|---|---|
| Age, y | .17 | .95 | ||||
| Median | 67 | 69 | 68 | 69 | ||
| Range | 60-79 | 60-83 | 60-81 | 60-83 | ||
| Sex, no. (%) | .52 | .11 | ||||
| Male | 46 (58) | 41 (52) | 38 (48) | 49 (62) | ||
| Female | 33 (42) | 38 (48) | 41 (52) | 30 (38) | ||
| Race, no. (%) | .40 | 1.0 | ||||
| White | 73 (94) | 68 (89) | 70 (92) | 71 (91) | ||
| Nonwhite | 5 (6) | 8 (11) | 6 (8) | 7 (9) | ||
| Hemoglobin, g/dL | .43 | .76 | ||||
| Median | 9.6 | 9.5 | 9.5 | 9.5 | ||
| Range | 5.4-15.0 | 6.8-14.5 | 5.4-13.6 | 6.0-15.0 | ||
| Platelet count, ×109/L | .31 | .51 | ||||
| Median | 55 | 67 | 69 | 55 | ||
| Range | 5-481 | 4-850 | 4-271 | 11-850 | ||
| WBC count, ×109/L | .78 | .005 | ||||
| Median | 27.8 | 33.5 | 20.6 | 38.0 | ||
| Range | 1.4-450.0 | 1.0-173.1 | 1.1-234.5 | 1.0-450.0 | ||
| Blood blasts, % | .36 | < .001 | ||||
| Median | 52 | 59 | 34 | 68 | ||
| Range | 0–97 | 0–99 | 0–93 | 0–99 | ||
| BM blasts, % | .80 | .001 | ||||
| Median | 70 | 67 | 59 | 75 | ||
| Range | 11-97 | 7-97 | 7-97 | 23-97 | ||
| Extramedullary involvement, no. (%) | 16 (21) | 19 (25) | .70 | 16 (21) | 19 (25) | .56 |
| NPM1, no. (%) | < .001 | .33 | ||||
| Mutated | 64 (81) | 33 (42) | 45 (57) | 52 (66) | ||
| Wild-type | 15 (19) | 46 (58) | 34 (43) | 27 (34) | ||
| FLT3-ITD, no. (%) | .14 | < .001 | ||||
| Present | 24 (30) | 34 (43) | 12 (15) | 46 (58) | ||
| Absent | 55 (70) | 45 (57) | 67 (85) | 33 (42) | ||
| FLT3-TKD, no. (%) | .61 | .61 | ||||
| Present | 10 (13) | 7 (9) | 10 (13) | 7 (9) | ||
| Absent | 69 (87) | 72 (91) | 69 (87) | 72 (91) | ||
| WT1, no. (%) | .21 | .21 | ||||
| Mutated | 3 (4) | 8 (10) | 3 (4) | 8 (10) | ||
| Wild-type | 76 (96) | 71 (90) | 76 (96) | 71 (90) | ||
| CEBPA, no. (%) | .02 | .65 | ||||
| Mutated | 6 (8) | 17 (22) | 10 (13) | 13 (16) | ||
| Wild-type | 73 (92) | 62 (78) | 69 (87) | 66 (84) | ||
| IDH1, no. (%) | .09 | .40 | ||||
| Mutated | 4 (6) | 10 (17) | 5 (8) | 9 (15) | ||
| Wild-type | 59 (94) | 50 (83) | 59 (92) | 53 (85) | ||
| IDH2*, no. (%) | .30 | .10 | ||||
| R140 IDH2 | 18 (29) | 7 (12) | 17 (28) | 8 (13) | ||
| R172 IDH2 | 0 (0) | 5 (8) | 2 (3) | 3 (5) | ||
| Wild-type | 45 (71) | 48 (80) | 42 (69) | 51 (82) | ||
| MLL-PTD, no. (%) | .68 | .42 | ||||
| Present | 2 (4) | 4 (7) | 4 (7) | 2 (3) | ||
| Absent | 55 (96) | 55 (93) | 51 (93) | 59 (97) | ||
| ERG expression†, no. (%) | < .001 | |||||
| Low | 51 (65) | 28 (35) | ||||
| High | 28 (35) | 51 (65) | ||||
| BAALC expression†, no. (%) | < .001 | |||||
| Low | 51 (65) | 28 (35) | ||||
| High | 28 (35) | 51 (65) |
BM, bone marrow; FLT3-ITD, internal tandem duplication of the FLT3 gene; FLT3-TKD, tyrosine kinase domain mutation of the FLT3 gene; MLL-PTD, partial tandem duplication of the MLL gene; WBC, white blood count.
P value is for the comparison of IDH2 mutated (R140 or R172) versus IDH2 wild-type.
The median expression value was used as a cut point.